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Introduction 
Several lines of evidence imply early alterations in endocannabinoid and phosphodiesterase 
10A (PDE10A) signaling in Huntington's disease (HD). Using [18F]MK-9470 and 
[18F]JNJ42259152 small-animal PET, we investigated for the first time cerebral changes in 
type 1 cannabinoid (CB1) receptor binding and PDE10A levels in vivo in pre-, early- and late 
symptomatic HD (R6/2) mice, in relation to brain morphology (MRI) and motor function. 
 
Methods 
Ten R6/2 and 16 wild-type (WT) mice were investigated at 3 different time points between 
the age of 4 and 13 weeks. Parametric CB1 receptor and PDE10A images were anatomically 
standardized to Paxinos space and analyzed voxel-wise. Volumetric microMRI imaging was 
performed to assess HD pathology.  
 
Results 
In R6/2 mice, CB1 receptor binding was decreased in comparison to WT in the bilateral 
caudateputamen, globus pallidus and thalamic nucleus at week 5 (-8.1%, pheight =1.7.10
-5). 
Longitudinal follow-up showed further progressive decline compared to controls in a cluster 
comprising the bilateral hippocampus, caudate-putamen, globus pallidus, superior colliculus, 
thalamic nucleus and cerebellum (late vs. presymptomatic age: -13.7±3.1% for R6/2 and 
+1.5±4.0% for WT; pheight =1.9.10
-5; Fig. 1). In R6/2 mice, PDE10A binding potential also 
decreased over time, to reach significance at early and late symptomatic HD (late vs. 
presymptomatic age: -79.1±1.9% for R6/2 and +2.1±2.7% for WT; pheight =1.5.10
-4; Fig. 2). 
The observed changes in CB1 receptor and PDE10A binding were correlated to anomalies 
exhibited by R6/2 animals in motor function, while no correlation was found with MRI-based 
striatal volume.  
 
Conclusions 
Our findings point to early regional dysfunctions in endocannabinoid and PDE10A signaling, 
involving the caudate-putamen and lateral globus pallidus, that may play a detrimental role in 
the progression of the disease in R6/2 animals. PET quantification of in vivo CB1 and/or 
PDE10A binding may thus be useful early biomarkers for HD. Our results also provide 
evidence of subtle motor deficits at earlier stages than previously described.  
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